Amylyx Pharmaceuticals, Inc.
AMLX
$14.48
$0.271.87%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -665.00K | -249.00K | -1.27M | 87.37M | 196.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -665.00K | -249.00K | -1.27M | 87.37M | 196.49M |
| Cost of Revenue | 55.88M | 94.27M | 97.82M | 228.72M | 296.30M |
| Gross Profit | -56.55M | -94.52M | -99.09M | -141.35M | -99.82M |
| SG&A Expenses | 64.59M | 66.25M | 72.26M | 114.33M | 149.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 156.68M | 196.73M | 206.28M | 379.25M | 445.78M |
| Operating Income | -157.34M | -196.98M | -207.55M | -291.88M | -249.29M |
| Income Before Tax | -149.92M | -188.24M | -219.49M | -302.14M | -257.48M |
| Income Tax Expenses | -635.00K | -635.00K | -635.00K | -393.00K | 1.99M |
| Earnings from Continuing Operations | -149.28 | -187.60 | -218.86 | -301.74 | -259.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -149.28M | -187.60M | -218.86M | -301.74M | -259.47M |
| EBIT | -157.34M | -196.98M | -207.55M | -291.88M | -249.29M |
| EBITDA | -156.76M | -196.30M | -206.81M | -290.98M | -248.25M |
| EPS Basic | -1.80 | -2.50 | -3.10 | -4.43 | -3.82 |
| Normalized Basic EPS | -1.22 | -1.66 | -1.82 | -2.66 | -2.25 |
| EPS Diluted | -1.80 | -2.50 | -3.10 | -4.43 | -3.82 |
| Normalized Diluted EPS | -1.22 | -1.66 | -1.82 | -2.66 | -2.25 |
| Average Basic Shares Outstanding | 336.76M | 311.52M | 290.41M | 272.56M | 271.39M |
| Average Diluted Shares Outstanding | 336.76M | 311.52M | 290.41M | 272.56M | 273.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |